In a cluster-randomized , crossover trial with strategies rotated in 4-month periods , we tested the noninferiority of the beta-lactam strategy to the beta-lactam-macrolide and fluoroquinolone strategies with respect to 90-day mortality , in an intention-to-treat analysis , using a noninferiority margin of 3 percentage points and a two-sided 90 % confidence interval .